This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Neuro-otology  • Hearing Loss/ Deafness  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Bradford J. May, PhD; Michael Guarnieri, PhD; Benjamin S. Carson Sr, MD; Abdul Bachani, BS; George I. Jallo, MD

Arch Otolaryngol Head Neck Surg. 2004;130:1411-1415.

Objective  To isolate the central auditory neurotoxicity of carboplatin from its well-established ototoxic effects.

Design  The "best-case scenario" of targeted drug delivery to brain cancer was simulated by infusing carboplatin directly into the brainstem of cynomolgus monkeys with chronically implanted catheters. Because this manner of drug administration produced low levels of carboplatin in spinal fluid and blood, it was assumed that resulting deficits were dictated by the central auditory neurotoxicity of platinum compounds and not peripheral ototoxic effects. The magnitude of this hearing loss was estimated by comparing the auditory brainstem response thresholds of treated monkeys with results from normal controls.

Subjects  Six adult male cynomolgus monkeys (Macaca fascicularis) weighing 4 to 6 kg (3 received carboplatin treatment and 3 served as normal controls).

Intervention  Brainstem infusions of carboplatin.

Results  The average threshold of carboplatin-treated monkeys was elevated 8.8 dB (SD = 7.3 dB) relative to normal controls 6 months after the termination of drug delivery and increased to 10.7 dB with less variation between subjects (SD = 5.6 dB) 1 year after drug treatment. Although small in magnitude, the hearing loss was statistically significant (P<.05).

Conclusions  Brainstem infusions of carboplatin induced some degree of hearing impairment in all treated monkeys. These threshold elevations were modest compared with the ototoxic effects that have been reported after systemic doses of carboplatin. Our findings suggest that the neurotoxic sensitivity of cochlear hair cells is not shared by neurons in the central auditory pathways. As a result, methods for reducing the ototoxic effects of chemotherapy remain a viable strategy for preserving auditory function in patients with brain cancer.

Author Affiliations: Departments of Otolaryngology–Head and Neck Surgery (Dr May) and Neurosurgery (Drs Guarnieri, Carson and Jallo and Mr Bachani), Johns Hopkins University, Baltimore, Md.